These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20482306)

  • 1. Extended-release lamotrigine in the treatment of patients with epilepsy.
    Syed TU; Sajatovic M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1579-85. PubMed ID: 20482306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily lamotrigine extended release for epilepsy management.
    Rheims S; Ryvlin P
    Expert Rev Neurother; 2009 Feb; 9(2):167-73. PubMed ID: 19210192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy.
    Wechsler RT; Leroy R; Van Cott A; Hammer AE; Vuong A; Huffman R; VanLandingham K; Messenheimer JA
    Epilepsy Res; 2014 Aug; 108(6):1128-36. PubMed ID: 24888248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
    Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA
    Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamotrigine extended-release as adjunctive therapy for partial seizures.
    Naritoku DK; Warnock CR; Messenheimer JA; Borgohain R; Evers S; Guekht AB; Karlov VA; Lee BI; Pohl LR
    Neurology; 2007 Oct; 69(16):1610-8. PubMed ID: 17938371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamotrigine use in pregnancy.
    Moore JL; Aggarwal P
    Expert Opin Pharmacother; 2012 Jun; 13(8):1213-6. PubMed ID: 22594849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.
    Biton V; Shneker BF; Naritoku D; Hammer AE; Vuong A; Caldwell PT; Messenheimer JA
    Clin Drug Investig; 2013 May; 33(5):359-64. PubMed ID: 23475541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical efficacy of lamotrigine as an antiepileptic drug.
    Pellock JM
    Neurology; 1994 Nov; 44(11 Suppl 8):S29-35. PubMed ID: 7970004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands.
    Knoester PD; Belitser SV; Deckers CL; Keyser A; Renier WO; Egberts AC; Hekster YA
    J Clin Pharm Ther; 2004 Apr; 29(2):131-8. PubMed ID: 15068401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios.
    Lathers CM; Schraeder PL; Claycamp HG
    J Clin Pharmacol; 2003 May; 43(5):491-503. PubMed ID: 12751270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
    Montouris G; Abou-Khalil B
    Epilepsia; 2009 Sep; 50 Suppl 8():16-20. PubMed ID: 19702728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine.
    Steinbaugh L; Szaflarski JP
    Drug Des Devel Ther; 2010 Nov; 4():337-42. PubMed ID: 21151621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
    Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release drug formulations for the treatment of epilepsy.
    Brandt C; May TW
    Expert Opin Pharmacother; 2018 Jun; 19(8):843-850. PubMed ID: 29672177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation.
    Sunder TR; McKee JR; Hammer AE; Vuongc A
    Curr Med Res Opin; 2006 Apr; 22(4):693-702. PubMed ID: 16684430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of tolerability in elderly patients: changing to lamotrigine therapy.
    Evans BK; Kustra RP; Hammer AE
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):112-9. PubMed ID: 17719513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacological overview of lamotrigine for the treatment of epilepsy.
    Yasam VR; Jakki SL; Senthil V; Eswaramoorthy M; Shanmuganathan S; Arjunan K; Nanjan MJ
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1533-1546. PubMed ID: 27825017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations.
    Leppik IE; Hovinga CA
    Epilepsia; 2013 Jan; 54(1):28-35. PubMed ID: 23190215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy.
    Sale ME; Natarajan S; Biton V; Vuong A; Hammer AE; Messenheimer JA; Blum D
    Epilepsy Behav; 2005 Feb; 6(1):63-70. PubMed ID: 15652736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.